Catherine M. Engelbert - 05 Jun 2026 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Reporting relationship: Director
Issuer ticker: RPRX
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 16:22:37 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Weisberg, as Attorney-in-Fact for Catherine M. Engelbert

Key filing fact

Catherine M. Engelbert filed Form 4 for Royalty Pharma plc (RPRX) on 08 Jun 2026.

Key facts

This page summarizes Catherine M. Engelbert's Form 4 filing for Royalty Pharma plc (RPRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Jun 2026, 16:22.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796439 Primary reporting owner

Engelbert Catherine M.

Relationship: Director
Address: C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Catherine M. Engelbert
Signature date: 08 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPRX transaction

Class A Ordinary Shares

Award

Transaction value
Shares: +4,545
Change %: +8.9%
Price: $0.000000^*
Shares after: 55,673
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.